Starpharma Holdings Limited SPHRY Stock
Starpharma Holdings Limited Price Chart
Starpharma Holdings Limited SPHRY Financial and Trading Overview
| Starpharma Holdings Limited stock price | 5.3 USD |
| Previous Close | 5 USD |
| Open | 5 USD |
| Bid | 4.84 USD x 20000 |
| Ask | 5.3 USD x 20000 |
| Day's Range | 5 - 5 USD |
| 52 Week Range | 0.73 - 5.7 USD |
| Volume | 700 USD |
| Avg. Volume | 655 USD |
| Market Cap | 238.53M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | August 10, 2026 |
| 1y Target Est | N/A |
SPHRY Valuation Measures
| Enterprise Value | 153.5M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 18.829136 |
| Price/Book (mrq) | 13.878711 |
| Enterprise Value/Revenue | 12.117 |
| Enterprise Value/EBITDA | -23.42 |
Trading Information
Starpharma Holdings Limited Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 509.75% |
| S&P500 52-Week Change | 19.66% |
| 52 Week High | 5.7 USD |
| 52 Week Low | 0.73 USD |
| 50-Day Moving Average | 4.88 USD |
| 200-Day Moving Average | 3.81 USD |
SPHRY Share Statistics
| Avg. Volume (3 month) | 655 USD |
| Avg. Daily Volume (10-Days) | 490 USD |
| Shares Outstanding | 47.71M |
| Float | 24.05M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | -58.92% |
| Operating Margin (ttm) | -583.74% |
| Gross Margin | 94.11% |
| EBITDA Margin | -51.73% |
Management Effectiveness
| Return on Assets (ttm) | -20.99% |
| Return on Equity (ttm) | -45.55% |
Income Statement
| Revenue (ttm) | 12.67M USD |
| Revenue Per Share (ttm) | 0.34 USD |
| Quarterly Revenue Growth (yoy) | -55.80% |
| Gross Profit (ttm) | 11.92M USD |
| EBITDA | -6554000 USD |
| Net Income Avi to Common (ttm) | -7465000 USD |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.02M USD |
| Total Cash Per Share (mrq) | 0.34 USD |
| Total Debt (mrq) | 707K USD |
| Total Debt/Equity (mrq) | 5.13 USD |
| Current Ratio (mrq) | 3.403 |
| Book Value Per Share (mrq) | 0.360264 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3210000 USD |
| Levered Free Cash Flow (ttm) | -2951625 USD |
Profile of Starpharma Holdings Limited
| Country | United States |
| State | VIC |
| City | Abbotsford |
| Address | 4-6 Southampton Crescent |
| ZIP | 3067 |
| Phone | 61 3 8532 2700 |
| Website | https://starpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.
Q&A For Starpharma Holdings Limited Stock
What is a current SPHRY stock price?
Starpharma Holdings Limited SPHRY stock price today per share is 5.3 USD.
How to purchase Starpharma Holdings Limited stock?
You can buy SPHRY shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Starpharma Holdings Limited?
The stock symbol or ticker of Starpharma Holdings Limited is SPHRY.
Which industry does the Starpharma Holdings Limited company belong to?
The Starpharma Holdings Limited industry is Biotechnology.
How many shares does Starpharma Holdings Limited have in circulation?
The max supply of Starpharma Holdings Limited shares is 47.71M.
What is Starpharma Holdings Limited Price to Earnings Ratio (PE Ratio)?
Starpharma Holdings Limited PE Ratio is now.
What was Starpharma Holdings Limited earnings per share over the trailing 12 months (TTM)?
Starpharma Holdings Limited EPS is -0.12 USD over the trailing 12 months.
Which sector does the Starpharma Holdings Limited company belong to?
The Starpharma Holdings Limited sector is Healthcare.
